

Development of best-in-class anti-OX40 therapeutic antibody candidate for the treatment of atopic dermatitis

Centenaire Biosciences, Inc.



IMMUNOLOGY	Candidate
Product Type	Antibody
Indication	Atopic Dermatitis
Target	OX40
MoA(Mechanism of Action)	Long term suppression of pathogenic T cells by blocking OX40 Amelioration of AD by suppression of disease-related cytokines
Competitiveness	Best-in-class affinity (Lead 41pM vs. Rocatinlimab 1.76nM; SPR) Best-in-class potency of pathogenic T cell suppression Extension of half-life and minimization of potential safety risk Low viscosity in high concentration
Development Stage	Candidate
Route of Administration	S.C. (Subcutaneous injection)

Any unauthorized distribution or reproduction of this material is strictly prohibited.